Clinical trial results reported Monday by Amgen may be enough to confirm the U.S. approval of its KRAS-targeting lung cancer drug called Lumakras. But the new data also show lung cancer patients are not benefiting from Lumakras as much as previously hoped, and liver toxicity remains a safety concern.
In the study, called CodeBreaK 200, Lumakras delayed tumor growth by a little more than one month compared to the standard chemotherapy, docetaxel — a lower-than-expected improvement that nonetheless achieved the main efficacy goal.
Create a display name to comment
This name will appear with your comment